PEPTIDE THERAPY / WEIGHT MANAGEMENT
Semaglutide
A once-weekly GLP-1 medication that helps regulate appetite and blood sugar, used as part of a medical weight-management plan.
- STATUS
- FDA-approved (brand-name) for type 2 diabetes and chronic weight management. Compounded versions are not FDA-approved.
- FORMS
- Weekly injection · Oral tablet (select formulations)
- ACCESS
- Prescription only · Telehealth in all 50 states
KEY TAKEAWAYS
- Mimics GLP-1, a natural hormone that signals fullness
- Studied in large clinical trials for weight management
- Works best with nutrition, activity, and ongoing follow-up
01 / OVERVIEW
What it is
Semaglutide is a GLP-1 receptor agonist — a lab-made version of glucagon-like peptide-1, a hormone your gut releases after eating. It was first approved for type 2 diabetes and later for chronic weight management in adults who meet certain criteria.
02 / MECHANISM
How it works
GLP-1 acts on the brain's appetite centers to increase feelings of fullness and reduce hunger, slows how quickly the stomach empties, and helps the pancreas release insulin when blood sugar rises. Together, these effects make it easier to eat less without constant hunger.
03 / EVIDENCE
What the research shows
In the STEP 1 trial, adults with obesity (without diabetes) who took weekly semaglutide alongside lifestyle changes lost about 15% of their body weight on average over 68 weeks, compared with about 2% on placebo. The SELECT trial later found a lower rate of major cardiovascular events in adults with established heart disease and overweight. Weight often returns if treatment stops, so plans are built for the long term.
04 / FIT
Who it may help
- Adults with obesity, or overweight with a weight-related health condition
- People who have struggled to lose weight with lifestyle changes alone
- Patients ready for regular follow-up and labs
05 / CAUTION
Who should avoid it
- Personal or family history of medullary thyroid cancer or MEN2
- Pregnancy, trying to conceive, or breastfeeding
- History of pancreatitis or certain gallbladder or kidney problems (discuss with your provider)
- Type 1 diabetes
06 / SAFETY
Possible side effects
- Nausea, vomiting, diarrhea, or constipation — most common early on and as doses change
- Reduced appetite, bloating, or heartburn
- Less common but serious: pancreatitis, gallbladder problems, low blood sugar (with some diabetes medicines), dehydration-related kidney problems
This is not a complete list. Your provider will review risks, benefits, and alternatives with you before starting any treatment.
EDUCATIONAL INFORMATIONThis page is for general education and is not medical advice. Semaglutide requires a prescription and is provided only after evaluation by a licensed provider when appropriate. When a compounded formulation is prescribed, it is prepared by a licensed U.S. pharmacy for you specifically. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.